Pink Sheet reporter and editors, and guest Michael McCaughan of Prevision Policy, continue the discussion of Donald Trump’s potential impact on the FDA, including how Robert F. Kennedy Jr. could change the agency as head of HHS (:37), whether lasting changes are coming to the FDA (13:00), and Commissioner Robert Califf’s request that industry help preserve the agency status quo (18:18). More On These Topics From The Pink Sheet Speed Of Novel Approvals In Jeopardy As RFK Jr. Lands US HHS Secretary Nod: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/speed-of-novel-approvals-in-jeopardy-as-rfk-jr-lands-us-hhs-secretary-nod-PBKQI3K2XBHK5F53ZBHRD6VX2Q/ Three Ways Trump Could Disrupt The US FDA: https://insights.citeline.com/pink-sheet/legislation/elections/three-ways-trump-could-disrupt-the-us-fda-5KPABNKMKVBWNMFBQGU6H6ZWKU/ Industry Support Key To US FDA’s Prospects Under Trump, Califf Says: https://insights.citeline.com/pink-sheet/legislation/elections/industry-support-key-to-us-fdas-prospects-under-trump-califf-says-73IBZRFLQVEERACL64N74IK5GM/ Republican Sweep Creates Smoother Path For Biopharma Policy Priorities: https://insights.citeline.com/pink-sheet/legislation/elections/republican-sweep-creates-smoother-path-for-biopharma-policy-priorities-R2UH6ULEN5DKHOOV3KGYSMSETE/ Anticipation And Trepidation About Trump’s Election Rise: https://insights.citeline.com/pink-sheet/legislation/elections/anticipation-and-trepidation-about-trumps-election-rise-YTCHNKQW4VA3PPY3GBF3BQLAOQ/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related